Compare GLP-1 Medications

Find detailed comparisons between different GLP-1 medications. Learn about their similarities, differences, and unique features to better understand your options.

Ozempic vs Wegovy

GLP-1

Weight Loss: 12-14% vs 15-17%

Uses: Type 2 Diabetes, Weight Management, Cardiovascular Risk Reduction, Obesity Treatment

FDA Approval: Ozempic (2017), Wegovy (2021)

Ozempic vs Saxenda

GLP-1

Weight Loss: 12-14% vs 5-10%

Uses: Type 2 Diabetes, Weight Management, Cardiovascular Risk Reduction, Obesity Treatment

FDA Approval: Ozempic (2017), Saxenda (2014)

Ozempic vs Mounjaro

Mixed

Weight Loss: 12-14% vs 15-20%

Uses: Type 2 Diabetes, Weight Management, Cardiovascular Risk Reduction, Blood Sugar Control

FDA Approval: Ozempic (2017), Mounjaro (2022)

Ozempic vs Zepbound

Mixed

Weight Loss: 12-14% vs 15-20%

Uses: Type 2 Diabetes, Weight Management, Cardiovascular Risk Reduction, Obesity Treatment

FDA Approval: Ozempic (2017), Zepbound (2023)

Ozempic vs Trulicity

GLP-1

Weight Loss: 12-14% vs 2-6%

Uses: Type 2 Diabetes, Weight Management, Cardiovascular Risk Reduction

FDA Approval: Ozempic (2017), Trulicity (2014)

Ozempic vs Byetta

GLP-1

Weight Loss: 12-14% vs 2-6%

Uses: Type 2 Diabetes, Weight Management, Cardiovascular Risk Reduction

FDA Approval: Ozempic (2017), Byetta (2005)

Ozempic vs Bydureon

GLP-1

Weight Loss: 12-14% vs 2-4%

Uses: Type 2 Diabetes, Weight Management, Cardiovascular Risk Reduction

FDA Approval: Ozempic (2017), Bydureon (2012)

Ozempic vs Lyxumia

GLP-1

Weight Loss: 12-14% vs 2-4%

Uses: Type 2 Diabetes, Weight Management, Cardiovascular Risk Reduction

FDA Approval: Ozempic (2017), Lyxumia (2016)

Wegovy vs Saxenda

GLP-1

Weight Loss: 15-17% vs 5-10%

Uses: Weight Management, Obesity Treatment

FDA Approval: Wegovy (2021), Saxenda (2014)

Wegovy vs Mounjaro

Mixed

Weight Loss: 15-17% vs 15-20%

Uses: Weight Management, Obesity Treatment, Type 2 Diabetes, Blood Sugar Control

FDA Approval: Wegovy (2021), Mounjaro (2022)

Wegovy vs Zepbound

Mixed

Weight Loss: 15-17% vs 15-20%

Uses: Weight Management, Obesity Treatment

FDA Approval: Wegovy (2021), Zepbound (2023)

Wegovy vs Trulicity

GLP-1

Weight Loss: 15-17% vs 2-6%

Uses: Weight Management, Obesity Treatment, Type 2 Diabetes, Cardiovascular Risk Reduction

FDA Approval: Wegovy (2021), Trulicity (2014)

Wegovy vs Byetta

GLP-1

Weight Loss: 15-17% vs 2-6%

Uses: Weight Management, Obesity Treatment, Type 2 Diabetes

FDA Approval: Wegovy (2021), Byetta (2005)

Wegovy vs Bydureon

GLP-1

Weight Loss: 15-17% vs 2-4%

Uses: Weight Management, Obesity Treatment, Type 2 Diabetes

FDA Approval: Wegovy (2021), Bydureon (2012)

Wegovy vs Lyxumia

GLP-1

Weight Loss: 15-17% vs 2-4%

Uses: Weight Management, Obesity Treatment, Type 2 Diabetes

FDA Approval: Wegovy (2021), Lyxumia (2016)

Saxenda vs Mounjaro

Mixed

Weight Loss: 5-10% vs 15-20%

Uses: Weight Management, Obesity Treatment, Type 2 Diabetes, Blood Sugar Control

FDA Approval: Saxenda (2014), Mounjaro (2022)

Saxenda vs Zepbound

Mixed

Weight Loss: 5-10% vs 15-20%

Uses: Weight Management, Obesity Treatment

FDA Approval: Saxenda (2014), Zepbound (2023)

Saxenda vs Trulicity

GLP-1

Weight Loss: 5-10% vs 2-6%

Uses: Weight Management, Obesity Treatment, Type 2 Diabetes, Cardiovascular Risk Reduction

FDA Approval: Saxenda (2014), Trulicity (2014)

Saxenda vs Byetta

GLP-1

Weight Loss: 5-10% vs 2-6%

Uses: Weight Management, Obesity Treatment, Type 2 Diabetes

FDA Approval: Saxenda (2014), Byetta (2005)

Saxenda vs Bydureon

GLP-1

Weight Loss: 5-10% vs 2-4%

Uses: Weight Management, Obesity Treatment, Type 2 Diabetes

FDA Approval: Saxenda (2014), Bydureon (2012)

Saxenda vs Lyxumia

GLP-1

Weight Loss: 5-10% vs 2-4%

Uses: Weight Management, Obesity Treatment, Type 2 Diabetes

FDA Approval: Saxenda (2014), Lyxumia (2016)

Mounjaro vs Zepbound

GLP-1/GIP

Weight Loss: 15-20% vs 15-20%

Uses: Type 2 Diabetes, Weight Management, Blood Sugar Control, Obesity Treatment

FDA Approval: Mounjaro (2022), Zepbound (2023)

Mounjaro vs Trulicity

Mixed

Weight Loss: 15-20% vs 2-6%

Uses: Type 2 Diabetes, Weight Management, Blood Sugar Control, Cardiovascular Risk Reduction

FDA Approval: Mounjaro (2022), Trulicity (2014)

Mounjaro vs Byetta

Mixed

Weight Loss: 15-20% vs 2-6%

Uses: Type 2 Diabetes, Weight Management, Blood Sugar Control

FDA Approval: Mounjaro (2022), Byetta (2005)

Mounjaro vs Bydureon

Mixed

Weight Loss: 15-20% vs 2-4%

Uses: Type 2 Diabetes, Weight Management, Blood Sugar Control

FDA Approval: Mounjaro (2022), Bydureon (2012)

Mounjaro vs Lyxumia

Mixed

Weight Loss: 15-20% vs 2-4%

Uses: Type 2 Diabetes, Weight Management, Blood Sugar Control

FDA Approval: Mounjaro (2022), Lyxumia (2016)

Zepbound vs Trulicity

Mixed

Weight Loss: 15-20% vs 2-6%

Uses: Weight Management, Obesity Treatment, Type 2 Diabetes, Cardiovascular Risk Reduction

FDA Approval: Zepbound (2023), Trulicity (2014)

Zepbound vs Byetta

Mixed

Weight Loss: 15-20% vs 2-6%

Uses: Weight Management, Obesity Treatment, Type 2 Diabetes

FDA Approval: Zepbound (2023), Byetta (2005)

Zepbound vs Bydureon

Mixed

Weight Loss: 15-20% vs 2-4%

Uses: Weight Management, Obesity Treatment, Type 2 Diabetes

FDA Approval: Zepbound (2023), Bydureon (2012)

Zepbound vs Lyxumia

Mixed

Weight Loss: 15-20% vs 2-4%

Uses: Weight Management, Obesity Treatment, Type 2 Diabetes

FDA Approval: Zepbound (2023), Lyxumia (2016)

Trulicity vs Byetta

GLP-1

Weight Loss: 2-6% vs 2-6%

Uses: Type 2 Diabetes, Cardiovascular Risk Reduction

FDA Approval: Trulicity (2014), Byetta (2005)

Trulicity vs Bydureon

GLP-1

Weight Loss: 2-6% vs 2-4%

Uses: Type 2 Diabetes, Cardiovascular Risk Reduction

FDA Approval: Trulicity (2014), Bydureon (2012)

Trulicity vs Lyxumia

GLP-1

Weight Loss: 2-6% vs 2-4%

Uses: Type 2 Diabetes, Cardiovascular Risk Reduction

FDA Approval: Trulicity (2014), Lyxumia (2016)

Byetta vs Bydureon

GLP-1

Weight Loss: 2-6% vs 2-4%

Uses: Type 2 Diabetes

FDA Approval: Byetta (2005), Bydureon (2012)

Byetta vs Lyxumia

GLP-1

Weight Loss: 2-6% vs 2-4%

Uses: Type 2 Diabetes

FDA Approval: Byetta (2005), Lyxumia (2016)

Bydureon vs Lyxumia

GLP-1

Weight Loss: 2-4% vs 2-4%

Uses: Type 2 Diabetes

FDA Approval: Bydureon (2012), Lyxumia (2016)

Medical Disclaimer: These comparisons are for informational purposes only. Always consult with your healthcare provider to determine which medication is most appropriate for your specific situation.

ShotWise App Interface

Track Your GLP-1 Journey with ShotWise

Get personalized dose tracking, side effect monitoring, and weight loss progress tracking all in one place. Join thousands of others managing their GLP-1 medications effectively.

Download ShotWise